Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Novartis Posts 14 Percent Drop In 1Q Profit

By R&D Editors | April 23, 2009

GENEVA (AP) – Novartis AG reported a 14 percent decline in first-quarter net profit in part due to shifts in currency values, as well as the cost of financing its takeover of the Alcon eye care company.

Novartis said the profit of $1.98 billion compared with $2.3 billion in the first quarter of 2008, but that its pharmaceuticals division performed well, with recently launched products rejuvenating the portfolio.

It cited the first regulatory approval of the drug Afinitor against kidney cancer in the United States and the approval in Europe and the US of the new Ixiaro vaccine against Japanese encephalitis.

‘New products fueled ongoing momentum in pharmaceuticals,’ said Chief Executive Daniel Vasella. ‘The fundamentals of the business remain positive.’

Profits fell because of currency losses, investments in new pharmaceuticals, reduced incomes from its Sandoz generic drugs unit and one-time gains in 2008.

‘A drop in average net liquidity and financing costs for the 25 percent Alcon stake, which was acquired in 2008, further reduced non-operating income in the 2009 quarter,’ it said.

He said that because of ‘the uncertain economy and currency market volatility’ the company would enhance productivity and manage costs.

‘Our aim in 2009 remains to again deliver record underlying net sales and earnings excluding currency effects,’ Vasella said.

Novartis said it had net sales for the first three months of $9.7 billion, down two percent from $9.9 billion in the same period of last year.

Novartis shares on the Zurich exchange rose 3.9 percent to 43.20 Swiss francs ($47.02).

Vontobel analysts said that in general the Novartis results met expectations, with profits somewhat better than anticipated and sales somewhat less.

Analysts at the Zurich Kantonalbank gave Novartis a ‘slightly positive rating.’ They said the pharma division was showing strength again but that its sales of blood-pressure drug Diovan and its best-selling anticancer drug Glivec – known as Gleevec in the United States – had fallen short of their expectations.

Diovan brought in $1.4 billion, with sales growing 3 percent in the United States and 10 percent elsewhere. U.S. sales were ‘hampered by inventory reductions among some wholesalers,’ Novartis said.

It said Glivec sales for the quarter were $894 million, a slight increase over the fourth quarter of last year, but a 13 percent growth in local currencies. The drug is targeted for certain forms of chronic myeloid leukemia and gastrointestinal stromal tumors.

Release Date: April 23, 2009
Source: Associated Press

Related Articles Read More >

2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE